The Global Multiple Sclerosis Market 2009-2024

March 20, 2009 - PRLog -- Report Details
Global Multiple Sclerosis Market will expand steadily from 2009 to 2024 - new report explains

The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those revenues will exceed $9bn during the second half of next decade, our new study shows. The World Health Organization estimates that over 2.5 million people suffer from multiple sclerosis worldwide. The prevalence and onset of MS in children and adults is expected to rise steadily. Global sales for MS therapies will rise accordingly, due to epidemiological, healthcare and commercial drivers. In this new market-based study - The Global Multiple Sclerosis Market 2009-2024 – we show and explain those trends in detail. This report will provide you with the analytical information that you need to understand current trends and future directions in the MS market area, the successful drugs being introduced and where the future successful growth of the market lies.

The Global Multiple Sclerosis Market 2009-2024 commercially analyses both leading and emergent treatments, with key companies and products discussed comprehensively. In particular, we discuss prospects for the following MS drugs:
- Tysabri
- Avonex
- Copaxone
- Betaferon
- Rebif.

Contemporary disease-modifying drugs for MS are administered intravenously, intramuscularly or subcutaneously, typically with discomfort to patients. We believe that orally-administered MS products will change the dynamics of the market area significantly. But you must understand now the commercial opportunities for those new agents and other exciting pipeline developments. This report answers those important questions and others, such as how the established MS products will fare competitively in the years ahead. Which will remain the most profitable and how will they be effected by new competition.

Comprehensive Market Analysis

The Global Multiple Sclerosis Market 2009-2024 examines the market sector critically through a comprehensive review of information sources, including first-hand primary consultations with relevant experts. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of important contemporary issues, especially relevant commercial drivers and restraints. Sources used include gold-standard commercial databases, in-house analytical tool, industry news, published reports, policy documents and economic research. Importantly, visiongain applies rigorous financial forecasting, qualitative analyses and the assessment of unmet needs. The result is a comprehensive market- and industry-centred report with detailed analysis and informed opinion.

Why you should buy The Global Multiple Sclerosis Market 2009-2024
By purchasing this report, you will receive the following benefits:
• Predicted revenues, growth rates and other key metrics for the global MS drugs market from 2009 to 2024
• Predicted revenues, growth rates and other key metrics for leading MS drugs worldwide from 2009 to 2024
• Predicted revenues, growth rates and other key metrics for MS drug sales in leading nations from 2009 to 2024
• Expert opinions from original visiongain interviews, with full interview transcripts – you will not find this information anywhere else
• Discussion of hot pipeline developments and up-and-coming products
• Discussion of forces that influence and characterise the market for MS treatments worldwide:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats
• Discussion of where the market is heading overall - both technologically and commercially - from the present onwards.

Nobody with an interest in the MS sector can afford to overlook this new market study from visiongain. Visiongain predicts that total revenues in the MS market will increase steadily throughout the forecast period, 2009 to 2024, with the most substantial growth occurring during a crucial period in the future. The market environment in many countries will change, with patent losses affecting current market leaders in MS treatment. New drug releases and reformulations of products will seek to increase therapeutic effectiveness, especially patient compliance. A new wave of oral drugs, currently in development, may well change the way MS treatments are delivered. Do you want to know more about this important market? You must order this report today.

Companies Listed
Active Biotech
Acorda Therapeutics
Aegera Idera
Allergan
Antisense Therapeutics
Apitope
Argyll Biotechnologies
Asphelia
Bayer-Schering
Bayhill Therapeutics
Berlex Laboratories
Biogen Idec
BioMS
BioPartners
BTG
Elan Pharmaceuticals
Eli Lilly
Fornix
GemacBio
Genentech
GlaxoSmithKline
GW Pharmaceuticals
IMS
Indevus
InterMune
Isis
Manhattan
Medarex
MediciNova
Merck KGaA
Merck Serono
Millennium
Mitsubishi Tanabe Pharma
Momenta Pharmaceuticals
Mylan
Natco Pharmaceuticals
Neuren
Novartis
Opexa
Orchestra Therapeutics
Otsuka Pharmaceuticals
PDL BioPharma
Pfizer
ReceptoPharm
Rentschler
Roche
Sanofi-Aventis
Teva
Transition
UCB

Visiongain ltd.
4th Floor,
BSG House,
226 236 City Road,
London
EC1V 2QY
United Kingdom

Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/Report.aspx?rid=374
Or http://www.visiongain.com

# # #

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services.